Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer.
Saved in:
| Title: | Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. |
|---|---|
| Authors: | Nie H; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Liao L; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zielinski RJ; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gomez JA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Basi AV; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Seeley EH; Department of Chemistry, The University of Texas at Austin, Austin, Texas., Tan L; Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bilecz AJ; Department of Obstetrics and Gynecology/Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Zhou W; Immunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania., Liu H; Immunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania., Wang C; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wu S; Immunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania., Qi Y; Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Miyamoto T; Immunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania., Severi F; Immunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania., Goldman AR; Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania., Gu S; Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sood AK; Department of Gynecological Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jazaeri AA; Department of Gynecological Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Drapkin R; Department of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Claiborne DT; Immunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania., Zhang N; Immunology, Microenvironment & Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania., Lorenzi PL; Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Burks JK; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lengyel E; Department of Obstetrics and Gynecology/Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Gottlieb E; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang R; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. |
| Source: | Cancer research [Cancer Res] 2025 Sep 15; Vol. 85 (18), pp. 3471-3489. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
